Immunotherapy in Lung Cancer Articles

Atezolizumab Boosts Survival in Patients With NSCLC, Liver Mets
Patients with non–small cell lung cancer and baseline liver metastases had improved progression-free survival and overall survival with the addition of immunotherapy to bevacizumab and a chemotherapy doublet.
Preoperative Immunotherapy Sends Positive Signals in 2 NSCLC Studies
Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.
Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years
After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.
Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal
Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.
Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC
The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.
Durvalumab Results Spark Hope for Progress in Advanced NSCLC
During an OncLive Peer Exchange® discussion, moderator Mark A. Socinski, MD, and other lung cancer experts from across the United States discuss what, in this context, the PACIFIC trial results mean for practicing oncologists and their patients. 
Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study. 
PD-L1 Status Central to NCCN Update for Frontline NSCLC Immunotherapy
PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.
Frontline Pembrolizumab Regimen Approved in Europe for Squamous NSCLC
The European Commission has approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the frontline treatment of patients with metastatic squamous non–small cell lung cancer.
Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC
Naiyer A. Rizvi, MD, highlights the progress made with immunotherapy in patients with NSCLC and shed light on where further research needs to go to move the needle forward.
Publication Bottom Border
Border Publication